Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:chemical_formula |
C20 H26 N4 O5 S
|
| gptkbp:class |
antisense oligonucleotide
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:developed_by |
gptkb:Sarepta_Therapeutics
|
| gptkbp:effective_date |
FDA approved
|
| https://www.w3.org/2000/01/rdf-schema#label |
Casimersen
|
| gptkbp:marketed_as |
Amondys 45
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:targets |
exon 51 of the dystrophin gene
|
| gptkbp:used_for |
gptkb:Duchenne_muscular_dystrophy
|
| gptkbp:bfsParent |
gptkb:Sarepta_Therapeutics
|
| gptkbp:bfsLayer |
5
|